Advancing the future of LNP and RNA characterization
24 Sept 2026Innovation in RNA-based therapeutics depends on scientific collaboration, advanced analytical technologies, and a deeper understanding of complex drug delivery systems. Hear from Jérémie Parot at SINTEF as he shares how their partnership with Waters has helped simplify and streamline the analysis of multiple critical quality attributes (CQAs) of lipid nanoparticles (LNPs) and RNA through user-friendly mass spectrometry, light scattering technology, and automation. Watch the full interview to discover how this collaboration is advancing analytical workflows and helping shape the future of LNP and RNA characterization.
About the company
Waters
Waters Corporation, the premium brand in the analytical instruments industry since 1958, creates business advantages for laboratory-dependent organizations by delivering practical and sustainable scientific innovation to enable significant advancements in such areas as: healthcare delivery, environmental management, food safety, chemical materials analysis, and water quality worldwide. Waters helps customers make profound discoveries, optimize laboratory operations, deliver product performance, and ensure regulatory compliance by providing a connected portfolio of separations and analytical science, mass spectrometry, laboratory informatics, as well as thermal analysis products.
What does this video cover?
Topics covered in this video
- How does the SINTEF-Waters partnership advance RNA-based therapeutics?
- How are lipid nanoparticle critical quality attributes analyzed?
- Which technologies streamline LNP and RNA characterization workflows?
- How does automation simplify mass spectrometry and light scattering analysis?
- What does Jérémie Parot reveal about future LNP analytical workflows?
